Clinuvel Pharmaceuticals 将来の成長

Future 基準チェック /56

Clinuvel Pharmaceuticals利益と収益がそれぞれ年間26.2%と21.4%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に19.9% 25.8%なると予測されています。

主要情報

26.2%

収益成長率

25.8%

EPS成長率

Biotechs 収益成長	15.4%
収益成長率	21.4%
将来の株主資本利益率	19.9%
アナリストカバレッジ	Good
最終更新日	18 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

CHIA:CUV - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2027	147	67	64	58	7
6/30/2026	111	41	49	47	7
6/30/2025	98	36	34	45	7
6/30/2024	88	36	31	37	N/A
3/31/2024	85	33	34	40	N/A
12/31/2023	82	30	36	42	N/A
9/30/2023	80	30	36	40	N/A
6/30/2023	78	31	36	37	N/A
3/31/2023	74	29	39	40	N/A
12/31/2022	70	26	43	44	N/A
9/30/2022	68	24	41	42	N/A
6/30/2022	66	21	39	40	N/A
3/31/2022	62	22	33	34	N/A
12/31/2021	57	24	27	27	N/A
9/30/2021	53	24	23	23	N/A
6/30/2021	48	25	18	19	N/A
3/31/2021	43	23	N/A	N/A	N/A
12/31/2020	38	21	17	19	N/A
9/30/2020	35	18	15	16	N/A
6/30/2020	33	15	13	14	N/A
3/31/2020	32	15	N/A	N/A	N/A
12/31/2019	32	15	16	16	N/A
9/30/2019	32	16	17	17	N/A
6/30/2019	31	18	18	18	N/A
3/31/2019	29	17	16	17	N/A
12/31/2018	27	16	15	15	N/A
9/30/2018	26	15	13	13	N/A
6/30/2018	25	13	12	12	N/A
3/31/2018	21	10	N/A	10	N/A
12/31/2017	17	6	N/A	8	N/A
9/30/2017	17	7	N/A	9	N/A
6/30/2017	17	7	N/A	10	N/A
3/31/2017	14	5	N/A	7	N/A
12/31/2016	12	3	N/A	4	N/A
9/30/2016	9	0	N/A	-1	N/A
6/30/2016	7	-3	N/A	-5	N/A
3/31/2016	5	-5	N/A	-5	N/A
12/31/2015	4	-6	N/A	-5	N/A
9/30/2015	4	-8	N/A	-5	N/A
6/30/2015	3	-10	N/A	-5	N/A
3/31/2015	3	-10	N/A	-5	N/A
12/31/2014	3	-10	N/A	-5	N/A
9/30/2014	3	-8	N/A	-5	N/A
6/30/2014	3	-6	N/A	-5	N/A
3/31/2014	3	-6	N/A	-6	N/A
12/31/2013	2	-6	N/A	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CUVの予測収益成長率 (年間26.2% ) は貯蓄率 ( 2.6% ) を上回っています。

収益対市場: CUVの収益 ( 26.2% ) はAustralian市場 ( 12.5% ) よりも速いペースで成長すると予測されています。

高成長収益: CUVの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: CUVの収益 ( 21.4% ) Australian市場 ( 5.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: CUVの収益 ( 21.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CUVの自己資本利益率は、3年後には低くなると予測されています ( 19.9 %)。

Clinuvel Pharmaceuticals 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Recent updates

CLINUVEL Files Canadian New Drug Submission for SCENESSE® in EPP

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Dividend of AU$0.05 announced

Full year 2024 earnings released: EPS: AU$0.71 (vs AU$0.62 in FY 2023)

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

CLINUVEL Announces A Novel Clinical Program

Investor sentiment deteriorates as stock falls 17%

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Full year 2023 earnings released: EPS: AU$0.62 (vs AU$0.42 in FY 2022)

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

Investor sentiment deteriorates as stock falls 19%

Now 22% undervalued

Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant

Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation

Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance

Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum

No independent directors

Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104

Investor sentiment improved over the past week

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Full year 2022 earnings released: EPS: AU$0.42 (vs AU$0.50 in FY 2021)

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

Investor sentiment improved over the past week

CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803)

Investor sentiment improved over the past week

Non-Executive Director recently sold AU$356k worth of stock

CLINUVEL Progresses CUV104 Vitiligo Study

CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke

No independent directors

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study

CEO, MD & Director recently sold AU$1.1m worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Now 28% undervalued after recent price drop

Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS AU$0.50 (vs AU$0.31 in FY 2020)

CEO, MD & Director recently sold AU$3.7m worth of stock

Non-Executive Director recently sold AU$692k worth of stock

Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with Afamelanotide

CEO, MD & Director recently sold AU$3.1m worth of stock

CEO, MD & Director recently sold AU$2.6m worth of stock

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Aug 31, 2021

Investor sentiment improved over the past week

Revenue misses expectations

First half 2021 earnings released: EPS AU$0.13 (vs AU$0.013 in 1H 2020)

New 90-day low: AU$20.11

Clinuvel Pharmaceuticals Limited to Report First Half, 2021 Results on Feb 26, 2021

Clinuvel Pharmaceuticals Limited Announces First Patient Dosed in SCENESSE DNA Repair Program

New 90-day low - AU$21.04

Earnings released

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘